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Abstract: Increasing evidence supports the beneficial effects of polyphenol-rich diets, including
the traditional Mediterranean diet, for the management of cardiovascular disease, obesity and
neurodegenerative diseases. However, a common concern when discussing the protective effects
of polyphenol-rich diets against diseases is whether these compounds are present in systemic
circulation in their intact/parent forms in order to exert their beneficial effects in vivo. Here, we
explore two common classes of dietary polyphenols, namely isoflavones and lignans, and their
gut microbial-derived metabolites for gut and blood–brain barrier predicted permeability, as well
as protection against neuroinflammatory stimuli in murine BV-2 microglia. Polyphenol microbial
metabolites (PMMs) generally showed greater permeability through artificial gut and blood–brain
barriers compared to their parent compounds. The parent polyphenols and their corresponding
PMMs were evaluated for protective effects against lipopolysaccharide-induced inflammation in
BV-2 microglia. The lignan-derived PMMs, equol and enterolactone, exhibited protective effects
against nitric oxide production, as well as against pro-inflammatory cytokines (IL-6 and TNF-α) in
BV-2 microglia. Therefore, PMMs may contribute, in large part, to the beneficial effects attributed to
polyphenol-rich diets, further supporting the important role of gut microbiota in human health and
disease prevention.
Keywords: polyphenol; gut microbial metabolites; permeability; equol; enterodiol;
enterolactone; inflammation
1. Introduction
In the United States, obesity is a growing epidemic. There have been many studies that link
obesity to an increased risk of developing other diseases, such as cardiovascular disease, diabetes,
and Alzheimer’s disease [1]. A quantitative systematic review estimated that the United States spent
$113.9 billion dollars total, or 4.8% of all healthcare spending in 2008 on overweight and obesity
care [2]. The standard American diet consisting of high levels of saturated fat, sodium and sugars,
contributes to these staggering obesity numbers [3]. People abiding by alternative diets in countries
such as Greece and Italy exhibit decreased risks of obesity as well as confounding diseases such as
metabolic syndrome [4].
Increasing evidence supports the beneficial effects of a traditional Mediterranean diet in the
management of cardiovascular disease, obesity and most recently, neurodegenerative diseases [5].
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The Mediterranean diet is characterized by high intake of polyphenols and unsaturated fats, with
most of the beneficial effects from this diet being attributed to the high polyphenol intake [6,7]. There
has been an increased interest in polyphenols for the treatment of neurodegenerative diseases as they
exhibit the ability to cross the blood–brain barrier (BBB) and have a wide range of bioactive properties
including antioxidant, anti-inflammatory, anti-apoptotic and lipid-lowering properties [8,9].
Polyphenols are a large class of secondary metabolites produced via the shikimate-derived
phenylpropanoid or polyketide pathways, and they are characterized by the presence of two or
more benzene rings bearing hydroxyl group(s) and lack any nitrogenous functional group in their
core structure [10]. Polyphenols are further divided into several subclasses including stilbenes,
flavonoids, lignans, and phenolic acids [11]. Although polyphenols exhibit biological effects in a
variety of assays, their poor bioavailability, extensive phase-2 metabolism, and whether they achieve
physiologically relevant concentrations as their intact/parent forms to exert their protective effects,
have been questioned. Rather, a growing consensus is that dietary polyphenols are metabolized by
microbiota in the colon to yield bioactive gut microbial metabolites [12–16]. Herein, two common
classes of dietary polyphenols were investigated, isoflavones and lignans, as well as their known
polyphenol microbial metabolites (PMMs).
The isoflavones, genistein (GEN) and daidzein (DAI), are two soy-derived polyphenols that
have been extensively studied for their bioactivities. Structurally similar to estrogen, isoflavones
are comprised of a 3-phenylchromen-4-one backbone, modified by glycosides, O-substituents, and
prenylated derivatives [17]. They exhibit the ability to serve as antioxidants, alleviate oxidative stress,
and reduce the risk of hormone-dependent cancers [18–20]. GEN has been identified as a potential
nutraceutical for Alzheimer’s disease as it exhibits the ability to inhibit mitochondria-dependent
apoptosis, and alleviate β-amyloid neurotoxicity, providing neuroprotection [21–23]. DAI also shows
pro-apoptotic and neurotoxic effects against glutamate treatment in mouse hippocampal and cerebral
cell cultures [24]. When metabolized in the gut by intestinal microflora, these isoflavones are converted
into equol (EQ) (Figure 1) [25]. EQ has exhibited bioactive properties in cardiovascular disease, bone
health, and cancers [26]. A recent study identified EQ as protective against oxidative stress in microglia,
through the downregulation of neuronal apoptosis, and increased neurite growth [14].
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Figure 1. Overview of the polyphenol isoflavones and lignan parent compounds and their respective
polyphenol microbial metabolites produced by gut microflora. (Genistein = GEN, daidzein = DAI,
equol = EQ, secoisolariciresinol = SECO, enterodiol = ED, enterolactone = EL).
Lignans often have complex structures made up of C6 and C3 units [27]. In plant tissues, lignans
are often found as dimers and can be in the free state or sugar bound [28]. Data suggests a lignan-rich
diet has numerous benefits such as prevention of hormone-dependent tumors, decrease in plasma
cholesterol and glucose profiles, and delaying type 2 diabetes [29–31]. The common and prototypical
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dietary lignan, secoisolariciresinol (SECO), is known to be deglycosylated by bacteria and converted to
the PMMs enterodiol (ED) and enterolactone (EL) (Figure 1) [32].
A common question regarding dietary polyphenols is whether they are present in systemic
circulation in physiologically relevant concentrations to exert their biological effects. Polyphenol
concentrations in the blood generally range from 0.1–1.0µM [33]. However, certain phenolic metabolites
such as pyrogallol sulfate and catechol sulfate reached plasma concentrations ranging from 5–20 µM,
while their parent compounds were undetected [34]. Absorption through the GI tract is complex as
the pH changes as compounds traverse through the stomach to the intestines, which changes the
bioavailability of substances [35]. The high-throughput parallel artificial membrane permeability assay
(PAMPA) is used to determine permeability properties related to the transcellular in vivo absorption
process of large compound libraries [36]. PAMPA has become a robust, versatile method for predicting
passive permeability of compounds through the gastrointestinal (GI) track, the BBB, and skin [37,38].
A major concern for the development of pharmaceuticals for CNS-related diseases is the ability of
compounds to cross the BBB, therefore it is of high importance to evaluate this ability early in drug
discovery [39]. The BBB is a lining of endothelial cells that protects the brain from the peripheral
nervous system [40]. PAMPA uses a combination of phospholipids specific to the membrane being
tested along with a microfiber filter to simulate the biological membrane [41].
Herein, we propose that certain PMMs derived from gut microflora metabolism of their parent
polyphenols are gut and BBB permeable and may provide protection against neuroinflammatory stress.
To explore this hypothesis, we first performed in silico screening for gut and BBB permeability and
then PAMPA of the parent polyphenols and their respective PMMs. Neuroprotective activity for all of
the compounds was then assessed by evaluating the levels of nitric oxide species and inflammatory
cytokines against LPS-induced inflammation in BV-2 murine microglia.
2. Results
2.1. SwissADME Predicts Polyphenol Microbial Metabolites Are Highly Gut and BBB Permeable
Utilizing SwissADME in silico modeling, BBB and gut permeability were predicted (Table 1). All
six of the compounds (parent polyphenols and their corresponding PMMs; Figure 1) were identified
as having high gut absorbance. The positive PAMPA gut controls, verapamil, ranitidine, ketoprofen
and antipyrine, all exhibited high gut permeability in the SwissADME predictor. ED, DAI and
EQ were predicted to have BBB permeability. The PAMPA BBB controls, both BBB permeable and
impermeable, were additionally screened in SwissADME, predicting passive permeability for verapamil
and corticosterone, but no BBB passive permeability by theophylline. After this predictive measure,
compounds were experimentally evaluated for passive permeability in the gut and BBB.
Table 1. In silico SwissADME predictive permeability of parent polyphenols and their microbial
metabolites in the gut and blood–brain barrier (BBB).
Compound Molecular Weight (g/mol) Gut Absorption BBB Permeability
SECO 362.42 High No
ED 302.36 High No
EL 298.33 High Yes
GEN 270.24 High No
DAI 254.24 High Yes
EQ 242.27 High Yes
Antipyrine 188.23 High Yes
Corticosterone 346.46 High Yes
Ketoprofen 254.28 High Yes
Ranitidine 314.40 High No
Theophylline 180.16 High No
Verapamil 454.60 High Yes
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2.2. SECO, GEN, DAI, EL, and EQ Exhibit High Permeability through PAMPA Gut
Compounds were evaluated for their permeability through simulation membranes of the gut
using PAMPA at pHs 5.0, 6.2, and 7.4 (Figure 2). Verapamil was used as the highly permeable control,
ranitidine as the low permeability, and antipyrine was used as an intermediate control. Ketoprofen was
used as a pH-dependent control. At pH 5, EL showed the highest permeability with a -log Pe value
of 4.27 ± 0.05, closely followed by EQ at 4.35 ± 0.11. At pH 6.2, EQ showed the highest permeability
with a -log Pe value of 4.20 ± 0.02 followed by EL at 4.37 ± 0.02. At pH 7.4, the same trend followed as
pH 6.2. SECO showed moderate permeability at all pHs tested, and DAI was most permeable at pHs 5
and 6.2. Parent compounds showed high permeability in all three pH treatments, while the metabolite
ED showed the lowest permeability of all test compounds in all three pH treatments tested (Figure 2).
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Figure 2. Parallel artificial membrane permeability assay (PAMPA) gut passive permeability at three
relevant pH levels: 5.0 (A), 6.2 (B), and 7.4 (C). Controls verapamil, antipyrine and ranitidine exhibit
high, medium and low penetrability, respectively. Ketoprofen shows variable permeability with
pH change.
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Figure 3. Assessment of blood–brain barrier passive permeability of polyphenols determined by PAMPA.
Positive (verapamil), intermediate (corticosterone) and low (theophylline) permeability controls.
2.4. Isoflavones and Lignans Show No Cytotoxicity in Murine Microglia
Isoflavones were administered at 20 µM, while lignans were dosed at 10 µM. Parent polyphenols
and PMMs were evaluated for cytotoxicity in murine microglia after a 24 h incubation period (Figure 4A,
Figure 5A). There were no significant reductions in cellular viability at each of the test concentrations,
thus indicating nontoxic levels.
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Figure 4. Effects of isoflavones against LPS-induced oxidative stress in BV-2 murine microglia.
Isoflavones exhibited no cytotoxic effects in murine microglia (A). Isoflavones (20 µM and 10 µM)
reduce nitric oxide production, as determined by the Griess Reagent (B). Isoflavones inhibited the
production of the pro-inflammatory cytokines, TNF-α (C) and IL-6 (D), in murine microglia. All data
expressed as mean ± standard error (n ≥ 3), significance was reported by analysis of variance (ANOVA)
followed with Dunnett multiple comparison testing. Significance as compared with control p ≤ 0.0001
(####); as compared with LPS, p ≤ 0.03 (*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****).
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Figure 5. Effects of lignans in murine microglia cells. Lignans were evaluated for cytotoxicity in BV-2
(A). Effect of lignan treatment (10 µM) on nitric oxide production, as determined by the Griess Reagent
(B). Lignans reduce the production of pro-inflammatory cytokines in murine microglia, TNF-α (C) and
IL-6 (D). All data expressed as mean ± standard error (n ≥ 3), significance was reported by analysis of
variance (ANOVA) followed with Dunnett multiple comparison testing. Significance as compared with
control p ≤ 0.0001 (####); as compared with LPS, p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****).
2.5. Isoflavones Reduce Nitric Oxide Species Production
Isoflavones were evaluated for their ability to reduce nitric oxide production after LPS induction,
as determined by the Griess Reagent (Figure 4B). Cells treated with LPS produced 41.5 ± 5.6 µM nitric
oxide species, significantly more than the control (0.4 ± 0.02 µM). GEN significantly reduced nitric
oxide at both 20 and 10 µM by 68% and 38%, respectively as compared to LPS alone. At 20 µM, DAI
and EQ also significantly reduced nitric oxide compared to LPS by 24 and 22%, respectively.
2.6. Isoflavones Reduce Pro-Inflammatory Cytokine Release
TNF-α was increased significantly to 687.7 ± 8.0 pg/mL after LPS stimulation, compared to
the unstimulated control, 115.4 ± 2.8 pg/mL (Figure 4C). All three isoflavones significantly reduced
TNF-α production compared to the LPS-induced treatment. GEN reduced TNF-α, by 29.1% and
16.6% at concentrations of 20 and 10 µM, respectively. DAI and EQ exhibited similar, albeit less
potent, protective abilities at both the high (20 µM) and low (10 µM) concentrations (Figure 4C).
IL-6 production was significantly increased by LPS (103.7 ± 3.6 pg/mL) compared to the control
(0.6 ± 0.05 pg/mL) (Figure 4D). All isoflavones were able to significantly reduce IL-6 production
compared to the LPS-induced treatment. GEN was the most effective, reducing IL-6 production by
80.4 and 34.0% at 20 and 10 µM, respectively (Figure 4D).
ANOVA followed by Tukey’s post hoc test was used to determine significant differences amongst
test compounds and anti-inflammatory potential. The 20 µM dose of GEN resulted in significantly
reduced concentrations of nitric oxide species, TNF-α, and IL-6 compared to all other test compounds
and concentrations (Tables S1–S3 in supplementary files), clearly showing GEN as the most potent
anti-inflammatory metabolite of the isoflavones and PMMs tested.
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2.7. Lignans Limit Nitric Oxide Species Production
Nitric oxide concentrations for vehicle-treated microglia were approximately 11.97 µM ± 0.07,
whereas LPS stimulation increased this concentration to 51.01 µM ± 1.23. SECO, ED and EL decreased
nitric oxide release by approximately 9.13 (46.35 µM ± 0.22), 8.54 (46.65 µM ± 0.36) and 30.07%
(35.67 µM ± 0.74), respectively (Figure 5B).
2.8. SECO, ED and EL Significantly Reduce IL-6 and TNF-α
As expected, IL-6 and TNF-α concentrations were elevated in LPS-treated microglia with
concentrations of 665.7 pg/mL ± 5.8, and 518.4 pg/mL ± 8.8, respectively (Figure 5C,D). IL-6
concentration decreased by 1.05 % (672.8 pg/mL ±13.9) in samples treated with SECO. ED and
EL pre-treated conditions decreased the release of IL-6 by approximately 3.74% (690.6 pg/mL ± 5.30)
and 26.41% (489.9 pg/mL ± 11.31), respectively. With respect to TNF-α, SECO, ED and EL reduced
cytokine release by 3.97% (497.8 pg/mL ± 12.42), 0.5% (515.8 pg/mL ± 7.12) and 29.47% (365.6 pg/mL
± 4.91), respectively. Like GEN above, EL showed significantly greater reduction of inflammatory
cytokines when compared to SECO and EL (Tables S4–S6).
3. Discussion
The overall health of humans and communities depends on many factors including genetics,
various environmental factors, and diet. Increased adherence to the Mediterranean diet was recently
correlated with a reduced risk of neurodegenerative diseases, including prodromal Parkinson’s
disease [5,42]. In this report, we sought to explore two common classes of polyphenols found in the
Mediterranean diet, namely isoflavones and lignans, to investigate the bioavailability and bioactivity
of these compounds and their metabolites.
Previously published literature suggests that for polyphenols to be bioactive, they must first be
transformed in the colon by the gut microbiota into molecularly unique metabolites [16]. Compounds
which are permeable through the gut mucosa enter the bloodstream and circulate in the body. The
in vivo permeability may change if these substances are compatible with active transporters, as well as
differences based on the individual’s GI environment and diet [43]. A number of factors contribute
to the absorption ability of a compound, namely, physicochemical (e.g., pKa, solubility, polarity),
physiological (e.g., GI pH, GI blood flow), and dosage form (e.g., tablet, capsule) [44].
To investigate the role of lignans, isoflavones, and PMMs in systemic circulation, we explored gut
permeability through in silico (SwissADME) and in vitro (PAMPA) models. Gut PAMPA results largely
coincided with those of in silico predictions and showed that the test compounds, with the exception
of ED, passively permeate the gut. The presence of O-methyls on SECO and lactone moiety on EL
may provide these molecules with additional lipophilicity needed to cross the membrane (Figure 1),
whereas ED contains free hydroxyl groups, which may reduce passive permeability. These data are
supported by previously published results such as the evaluation of GI absorption of alkaloids from
Coptis [45]. PAMPA is a useful tool for predicting a compound’s permeability through the human gut,
however, it only considers the rate of passive transport [36].
The BBB serves as a protective barrier of the brain, comprised of endothelial cells that create tight
junctions, allowing for extremely selective passive permeability [40]. This typically results in higher
penetrability by lipophilic compounds through the BBB [46]. Compounds that pass through the BBB
may influence the brain state and physiology. We sought to identify if the aforementioned isoflavones,
lignans, and PMMs can passively cross the BBB and could be relevant in modulating the pathogenic
features of neurodegenerative diseases.
Computational predictive software, SwissADME, identified EL, DAI and EQ as BBB-penetrable
molecules. Interestingly, neither GEN nor SECO were considered permeable. Furthermore, our
PAMPA in vitro study supported these results, reporting high permeability of EL and EQ. SECO and
ED exhibited no apparent permeability. The parent compounds of isoflavones, GEN and DAI, were
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identified as intermediate permeable compounds. Similar investigative strategies have identified high
permeability of compounds derived from natural sources through PAMPA–BBB [47]. While there are
many other factors that contribute to BBB permeability, such as plasma concentration, plasma binding,
and metabolic modifications by barrier enzymes, PAMPA is a good predictor of passive movement
across the BBB [35,46]. The relationship between gut and BBB permeability is further complicated by
presystemic metabolism. For instance, previous studies have shown that following gut metabolism, EL
predominantly exists as a glucuronide conjugate, certainly affecting its BBB permeability and overall
bioavailability [48].
We identified that these PMMs, specifically EL and EQ, passively cross both the gut and BBB
barriers. To further identify the potential bioactivities of these molecules, we examined their protective
ability against inflammation in microglia. Microglia are the resident macrophages of the brain that
work to eliminate debris from the brain [48]. However, continuous activation of microglia can lead to
the over-production of inflammatory cytokines, as identified in postmortem brains of Alzheimer’s and
Parkinson’s disease patients [49]. One mechanism of microglia activation is the increase in LPS levels
in peripheral blood, due to poor diet [50,51]. The continued elevated levels of these pro-inflammatory
cytokines, specifically IL-6 and TNF-α, can stimulate the recruitment and activation of other microglia,
further inducing the production of reactive oxygen species and nitric oxide species [52]. Nitric oxide
species at low doses is critical for maintaining healthy microglia and neuron function, but at high
doses can induce necrosis or apoptosis [53]. Phenolic compounds have previously been linked to
reduced microglia-induced neuroinflammation [54]. At 20 µM, all tested isoflavones were able to
significantly reduce nitric oxide production, and TNF-α and IL-6 concentrations compared to LPS
alone. These results are consistent with previous reports of isoflavones [14]. However, GEN clearly
showed the greatest anti-inflammatory properties when compared to SECO and EQ. Furthermore, we
subjected SECO and its microbial-derived metabolites to neuroprotective assays. Among the lignans
tested, only gut-derived metabolite EL was able to significantly reduce IL-6 and TNF-α production.
Additionally, EL showed significantly greater reduction in nitric oxide concentrations than its parent
metabolite and ED. Recent studies with certain polyphenol metabolites, namely gallic acid derivatives,
demonstrated that these metabolites pass across BBB endothelium and provide neuroprotective effects
through modulation of the NF-κB pathway [55]. It is clear from these previous studies and the work
presented here that the neuroprotective potential of BBB-permeable metabolites is an important area
for further investigation to understand the relationship between dietary intake of polyphenols and
brain health.
In summary, the fate of microbial metabolites is largely governed by their ability to permeate
through biological barriers. After investigating two classes of polyphenols often found in the
Mediterranean diet, namely, isoflavones and lignans, our data suggest that their gut microbial
metabolites, but not parent compounds, may enter the blood, cross the BBB and provide protection
against neuroinflammation. The isoflavone parent compound, DAI, exhibits high gut permeability, but
intermediate BBB permeability. DAI’s microbial metabolite, EQ, exhibits high permeability in both the
gut and BBB, as well as significantly reducing nitric oxide and the production of pro-inflammatory
cytokines in murine microglia. GEN shows permeability through both the gut and BBB and very
strong anti-inflammatory effects. However, gut microbial metabolism would likely limit the circulating
levels of GEN in the blood. The lignan SECO has extremely limited membrane permeability, but its gut
microbial metabolite EL passively penetrates both the gut and BBB. Additionally, EL was most effective
out of the lignans tested in inhibiting nitric oxide species and pro-inflammatory cytokines in vitro.
These data, supported by previously published literature, suggest the further investigation of
gut-microbial-derived metabolites, specifically EL and EQ, for the treatment of neurodegenerative
diseases both in vitro and in vivo. Furthermore, using a system like PAMPA can aid in refining in vitro
testing to ultimately inform the design of more efficacious animal studies.
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4. Materials and Methods
4.1. Compounds and Chemicals
Dimethylsulfoxide (DMSO) and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO, USA). Daidzein (DAI), (±) enterodiol (ED) (Cat# 45198-5MG-F),
(±) enterolactone (EL) (Cat# 45199-1MG-F), genistein (GEN) and (±) secoisolariciresinol (SECO) (Cat#
60372-5MG-F) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). S-Equol
was purchased from Chembest (Shanghai, China). Antipyrine, corticosterone, ketoprofen, ranitidine,
theophylline and verapamil were purchased as PAMPA controls from Pion, Inc. (Billerica, MA, USA).
4.2. In Silico ADME Predictors
The in silico tool SwissADME was used as a measure to predict BBB and gut permeability. Predicted
permeability was assessed for each individual compound and control, as previously explained [56].
4.3. Parallel Artificial Membrane Permeability Assay (PAMPA)
Parallel Artificial Membrane Permeability Assay was performed to analyze both blood–brain
barrier (BBB) and gut passive permeability. All materials for PAMPA were purchased from Pion, Inc.
(Billerica, MA, USA). Both the gut and BBB assays were performed according to the manufacturer’s
instructions. Briefly, test compounds and standards were prepared at 10 mM concentrations in DMSO.
For the gut assay, Prisma HT buffer was adjusted to pHs 5, 6.2, and 7.4 by adding 0.5 M NaOH. In the
deepwell plate provided by Pion, 1 mL of each pH-adjusted buffer was added to separate wells. For
each pH, 5 µL of the sample was added to the 1 mL of buffer then mixed thoroughly with a pipette,
diluting the sample to a final concentration of 50 µM. Next, 200 µl of the diluted sample was added to
the donor (bottom) plate from the Pion sandwich assay, 5 µL of GIT lipid matrix was added to the
membrane on the bottom of the acceptor plate, and 200 µL of acceptor sink buffer was added in each
well of the acceptor plate. The sandwich was assembled, and the plate incubated at room temperature
for 4 h undisturbed. In BBB assays, compounds (10 mM) were diluted to final concentrations of 50 µM
in Prisma HT Buffer (pH = 7.4). The PAMPA sandwich was created with the donor (bottom), BBB
artificial membrane, and brain sink buffer as the acceptor (top). The assay was performed for 1 h at
room temperature with shaking (60 µm) using the manufacturer-supplied GIT Box. After incubation,
the UV profiles of the donor and acceptor plates were read on the SpectraMax plate reader connected to
the PAMPA software. PAMPA software calculated the –log Pe values for each compound and standard
using the UV profiles of the donor and acceptor plates. Standards were all within 0.25 units of the
expected value provided by PAMPA and each sample was averaged with 4 replicates.
4.4. Cell Culture Conditions
Murine microglia (BV-2) were generously provided by Dr. Grace Sun of the University of Missouri
at Columbia. Cells were maintained in DMEM/F12 (Life Technologies, Gaithersburg, MD, USA)
supplemented with 10% (v/v) sterile filtered and heat inactivated Fetal Bovine Serum in addition
to 1% (v/v) Penicillin/Streptomycin Antibiotic Solution (Life Technologies, Gaithersburg, MD, USA).
Cells were incubated at approximately 65% relative humidity at 37 ◦C under atmospheric oxygen
and 5% CO2. Cells were passaged using Trypsin-EDTA (Life Technologies, Gaithersburg, MD USA),
enumerated, and checked for viability using Trypan blue (Sigma Aldrich, St. Louis, MO, USA) dye
exclusion. DMSO (Sigma Aldrich, St. Louis, MO, USA) was used to dissolve compounds and did not
exceed 0.1% when incubated with cells.
4.5. Cell Viability
The cytotoxicity of each compound was determined in BV-2. Briefly, cells were seeded in
96 white-walled, clear bottom plates at 100,000 cells/mL. Cells were allowed to adhere for 24 h.
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Compounds were prepared to 10 mM in DMSO, then diluted in serum-free media to yield concentrations
of 20 and 10 µM. Cells were treated with prepared concentrations of each compound for 24 h. Cellular
viability was determined as a percentage of control (DMSO) by Cell Titer Glo 2.0 (CTG; Promega,
Madison, WI, USA), read for luminescence on the SpectraMax M2 plate reader (Molecular Devices,
Sunnyvale, CA, USA).
4.6. LPS Stimulation of Murine Microglia BV-2 Cells
As previously published, BV-2 cells were seeded at a density of 100,000 cells/mL in 24-well
plates [57]. After reaching a confluency of 85%, cells were exposed to either DMSO, SECO (10 µM),
ED (10 µM), EL (10 µM), GEN (20, 10 µM), DAI (20, 10 µM), or EQ (20, 10 µM), for 1 h prior to incubation
of LPS (1 µg/mL) for 23 h. Media were collected, aliquoted for nitric oxide and cytokine analysis.
4.7. Quantification of Nitric Oxide
Nitric oxide was detected in BV-2 culture media following the stimulation of LPS for 24 h from
the previously described experiment by way of the Griess Assay (Promega, Madison WI), according to
the manufacturer’s protocol.
4.8. Measurement of IL-6 and TNF-α
IL-6 and TNF-α were measured from BV-2 media using Enzyme Linked Immunosorbent Assay
(ELISA) provided by Biolegend (San Diego, CA, USA) [57].
4.9. Statistical Analysis
All data are reported as mean ± standard errors of at least three independent biological samples.
The analysis of all cellular data was conducted by ANOVA followed by Dunnett’s test or Tukey’s test
for multiple comparisons of group means. The significance of the toxic agent compared to the control
group is presented as p ≤ 0.001 (###) and p ≤ 0.0001 (####). The significance for tests compared to toxic
treatment was defined as: p ≤ 0.03 (*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****). GraphPad
Prism software 7.0 (GraphPad Software, Inc., San Diego, CA, USA) was used for all statistical analysis
calculations and graphical representations.
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Table S6: Effect of lignans (SECO, ED, EL) on IL-6 production.
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